{"product_id":"crpharm-business-model-canvas","title":"China Resources Pharmaceutical Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina Resources Pharmaceutical: Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind China Resources Pharmaceutical Group's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances with Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group cultivates strategic alliances with a vast network of healthcare institutions, including hospitals and clinics, to guarantee extensive reach for its pharmaceutical offerings. These partnerships are fundamental for achieving deep market penetration and establishing direct engagement with healthcare professionals.  By the end of 2023, the group’s distribution capabilities spanned 28 provinces, effectively serving around 240,000 clients, a significant portion of which are medical institutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborations with Research and Development Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group actively partners with research and development firms to bolster its drug pipeline and drive innovation. These collaborations often take the form of joint ventures and licensing agreements, allowing the company to develop novel pharmaceutical products and improve existing ones.\u003c\/p\u003e\n\u003cp\u003eTo manage merger and acquisition risks and expedite strategic expansion within the pharmaceutical industry, China Resources Pharmaceutical is establishing an innovation investment fund. This strategic move is designed to accelerate growth by identifying and integrating promising new technologies and companies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group cultivates robust relationships with its procurement and supply chain partners, often entering into long-term agreements for essential raw materials, ingredients, and manufacturing supplies. These strategic alliances are fundamental to ensuring a consistent and streamlined supply chain. For instance, the company has established new procurement and sales framework agreements with CR Holdings, which are set to run from January 2025 through December 2027, highlighting a commitment to sustained collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains and Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group extends its market reach beyond its owned retail pharmacies by forging partnerships with independent retail pharmacy chains and distributors. This strategic approach significantly broadens its consumer accessibility and market presence for healthcare products. The Group’s commitment to a robust distribution network is underscored by its operation of 790 self-owned retail pharmacies, a figure that notably includes 272 specialized DTP (Direct-to-Patient) pharmacies.\u003c\/p\u003e\n\u003cp\u003eThese collaborations are crucial for ensuring that China Resources Pharmaceutical Group's diverse range of healthcare goods, from prescription medications to over-the-counter remedies, are readily available across a wider geographical footprint. By leveraging the existing infrastructure and customer base of these external partners, the Group can efficiently penetrate new markets and strengthen its position in established ones. \u003c\/p\u003e\n\u003cp\u003eKey aspects of these partnerships include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpanded Distribution Network:\u003c\/strong\u003e Collaborating with independent chains and distributors allows the Group to access a larger number of retail points, increasing product availability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Market Penetration:\u003c\/strong\u003e These alliances facilitate deeper penetration into diverse consumer segments and geographical areas where the Group may not have a direct physical presence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSynergistic Growth:\u003c\/strong\u003e Partnering with established pharmacy chains and distributors creates a mutually beneficial relationship, driving sales and market share for both parties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group actively partners with government agencies and regulatory bodies to navigate China's intricate pharmaceutical sector. These collaborations are crucial for ensuring adherence to evolving policies, particularly those concerning drug reimbursement and the often lengthy approval processes for new medications.  For instance, in 2024, the National Healthcare Security Administration (NHSA) continued to refine its national reimbursement drug list, impacting market access for pharmaceutical companies.\u003c\/p\u003e\n\u003cp\u003eThese key partnerships facilitate participation in vital national healthcare initiatives, such as public health programs and disease management strategies. By aligning with government objectives, the group strengthens its position within the healthcare ecosystem.  In 2024, significant government focus remained on expanding access to innovative therapies, a trend that shapes the strategic priorities of companies like China Resources Pharmaceutical Group.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Compliance:\u003c\/strong\u003e Maintaining close ties with bodies like the National Medical Products Administration (NMPA) ensures timely updates and adherence to stringent quality and safety standards.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Collaborations with the NHSA are vital for securing inclusion in national and provincial reimbursement drug lists, directly impacting sales and patient affordability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy Engagement:\u003c\/strong\u003e Proactive engagement with government entities allows the group to contribute to policy discussions, influencing the future landscape of pharmaceutical development and distribution in China.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Pharmaceutical Growth and Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group's key partnerships are essential for its operational success and market reach. These alliances span healthcare providers, research institutions, suppliers, and government bodies, ensuring a robust ecosystem for its pharmaceutical business.\u003c\/p\u003e\n\u003cp\u003eThe group's extensive distribution network, reaching approximately 240,000 clients by the end of 2023, is built on strong relationships with hospitals and clinics. Furthermore, collaborations with independent pharmacies and distributors, alongside its 790 self-owned retail pharmacies (including 272 DTP pharmacies), significantly amplify its market accessibility.\u003c\/p\u003e\n\u003cp\u003eStrategic R\u0026amp;D partnerships and an innovation investment fund are vital for pipeline development. Long-term agreements with procurement partners, like the framework agreements with CR Holdings from 2025-2027, secure the supply chain. Engagement with government agencies, such as the NHSA in 2024 regarding drug reimbursement lists, ensures regulatory compliance and market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003ePurpose\u003c\/th\u003e\n\u003cth\u003eKey Impact\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Institutions (Hospitals, Clinics)\u003c\/td\u003e\n\u003ctd\u003eExtensive reach, direct engagement with professionals\u003c\/td\u003e\n\u003ctd\u003eServes ~240,000 clients, including medical institutions (End of 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Firms\u003c\/td\u003e\n\u003ctd\u003eDrug pipeline enhancement, innovation\u003c\/td\u003e\n\u003ctd\u003eJoint ventures, licensing agreements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement \u0026amp; Supply Chain Partners\u003c\/td\u003e\n\u003ctd\u003eEnsuring consistent supply of raw materials\u003c\/td\u003e\n\u003ctd\u003eNew procurement framework with CR Holdings (2025-2027)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndependent Retail Pharmacies \u0026amp; Distributors\u003c\/td\u003e\n\u003ctd\u003eBroadening consumer accessibility\u003c\/td\u003e\n\u003ctd\u003eComplements 790 self-owned retail pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment Agencies (NHSA, NMPA)\u003c\/td\u003e\n\u003ctd\u003eRegulatory compliance, market access, policy engagement\u003c\/td\u003e\n\u003ctd\u003eNavigating 2024 NHSA reimbursement list refinements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis Business Model Canvas provides a comprehensive overview of China Resources Pharmaceutical Group's strategy, detailing its diverse customer segments, extensive distribution channels, and multi-faceted value propositions across R\u0026amp;D, manufacturing, and sales.\u003c\/p\u003e\n\u003cp\u003eIt reflects the company's integrated operations and strategic focus on innovation and market expansion, offering insights for informed decision-making and stakeholder engagement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe China Resources Pharmaceutical Group's Business Model Canvas offers a high-level, one-page snapshot, simplifying complex strategies to quickly identify core components and alleviate the pain point of information overload.\u003c\/p\u003e\n\u003cp\u003eThis concise, shareable, and editable format condenses the company's strategy into a digestible format, saving hours of formatting and structuring for executive summaries and team collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Pharmaceutical Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group's core activity is the relentless pursuit of innovation through significant investment in research and development. This dedication spans the discovery, development, and enhancement of a diverse portfolio of pharmaceutical products, covering critical therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eTheir R\u0026amp;D efforts are strategically focused on three key pillars: advanced chemical drugs, the rich heritage of traditional Chinese medicine (TCM), and cutting-edge biologics. This multi-pronged approach ensures a comprehensive strategy for addressing a wide range of health needs.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the company continued its integrated business model, actively engaging in R\u0026amp;D alongside manufacturing, extensive distribution networks, and a robust retail presence in the pharmaceutical and healthcare sectors. This synergy allows them to bring innovations from the lab to the patient effectively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing of Pharmaceutical and Healthcare Goods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group is deeply involved in the large-scale manufacturing of a broad spectrum of pharmaceutical and healthcare products. This includes everything from chemical drugs and traditional Chinese medicine (TCM) to everyday consumer healthcare items. The company manages its own production facilities, placing a strong emphasis on rigorous quality control throughout the entire manufacturing process.\u003c\/p\u003e\n\u003cp\u003eThis core manufacturing operation is a significant contributor to the Group's financial performance. In 2024, the manufacturing segment alone generated 18.0% of China Resources Pharmaceutical Group's total revenue, underscoring its importance to the company's overall business model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Distribution and Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group's core activities heavily rely on its robust pharmaceutical distribution and logistics network. This segment is the engine of the company's revenue, ensuring products reach healthcare providers and patients efficiently across China.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the medical distribution business was the dominant force, contributing a substantial 82.8% to the Group's overall revenue. This highlights the critical role of their distribution capabilities.\u003c\/p\u003e\n\u003cp\u003eAs the third-largest medical distributor in China, the company leverages its extensive warehousing and logistics infrastructure to manage a vast array of pharmaceutical products, underscoring its market position and operational scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperation of Retail Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group actively manages its proprietary retail pharmacy chain, offering direct consumer access to a wide array of healthcare goods, including prescription and over-the-counter medications. This operational arm is crucial for reaching end-users across mainland China and Hong Kong.\u003c\/p\u003e\n\u003cp\u003eIn 2024, the group's retail pharmacy segment continued to be a significant touchpoint for patients. For instance, as of the end of 2023, the company operated over 3,000 retail pharmacies, a figure expected to see modest growth through 2024 as they expand their footprint and service offerings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect Consumer Access:\u003c\/strong\u003e The pharmacies provide a direct channel for dispensing medications and health products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeographic Reach:\u003c\/strong\u003e Operations span both mainland China and Hong Kong, catering to diverse market needs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Portfolio:\u003c\/strong\u003e Offers a comprehensive range from prescription drugs to general health and wellness items.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Presence:\u003c\/strong\u003e Contributes significantly to brand visibility and customer engagement within the healthcare sector.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Mergers and Acquisitions (M\u0026amp;A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group strategically engages in mergers and acquisitions (M\u0026amp;A) to fuel growth, expand its footprint, and strengthen its competitive edge. These activities are central to its strategy for market share expansion and product portfolio enhancement.\u003c\/p\u003e\n\u003cp\u003eThe company actively integrates resources through M\u0026amp;A, aiming to achieve synergies and operational efficiencies. This approach allows them to quickly access new markets, technologies, and talent.\u003c\/p\u003e\n\u003cp\u003eRecent M\u0026amp;A moves highlight this strategy. For instance, acquiring stakes in KPC Pharmaceuticals and Anhui Lifang Pharmaceutical were key steps to bolster their market presence and overall competitiveness in the pharmaceutical sector.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e M\u0026amp;A allows China Resources Pharmaceutical Group to enter new geographic markets and gain access to a broader customer base.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio Enhancement:\u003c\/strong\u003e Acquisitions are used to broaden the company's range of pharmaceutical products, including innovative drugs and generics.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResource Integration:\u003c\/strong\u003e The group integrates acquired companies' research and development capabilities, manufacturing facilities, and distribution networks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Strengthening:\u003c\/strong\u003e By consolidating market share and acquiring complementary businesses, the company enhances its position against rivals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution Fuels Pharmaceutical Group's 82.8% Revenue Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChina Resources Pharmaceutical Group's key activities revolve around a vertically integrated model, encompassing R\u0026amp;D, manufacturing, extensive distribution, and retail operations. Their strategic focus on innovation spans chemical drugs, traditional Chinese medicine, and biologics, driving product development. In 2024, the company's distribution segment was the primary revenue driver, accounting for 82.8% of total revenue, underscoring its critical role in market reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 Revenue Contribution\u003c\/th\u003e\n\u003cth\u003eStrategic Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceutical Distribution\u003c\/td\u003e\n\u003ctd\u003e82.8%\u003c\/td\u003e\n\u003ctd\u003eExtensive warehousing and logistics, market leadership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e18.0%\u003c\/td\u003e\n\u003ctd\u003eDiverse product portfolio, rigorous quality control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eN\/A (Investment)\u003c\/td\u003e\n\u003ctd\u003eChemical drugs, TCM, biologics innovation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail Pharmacy\u003c\/td\u003e\n\u003ctd\u003eN\/A (Contribution to Brand)\u003c\/td\u003e\n\u003ctd\u003eOver 3,000 outlets, direct consumer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas for China Resources Pharmaceutical Group that you are previewing is the exact, complete document you will receive upon purchase. This isn't a sample or a mockup; it's a direct representation of the comprehensive analysis you'll get, ready for immediate use in your strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611127300473,"sku":"crpharm-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/crpharm-business-model-canvas.png?v=1754751318","url":"https:\/\/growthsharematrix.com\/products\/crpharm-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}